Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fcontent%2Fconference-reports%2Fcardiotoxicity-consider-switching-to-s-1-2%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=34.225.194.102&categories=Conference+Report+Article%7COncology%7CGastrointestinal+Cancer%7CGI+Cancer%7CASCO+2020): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Cardiotoxicity: consider switching to S-1 - Medical Conferences

Home > Oncology > ASCO 2020 > Gastrointestinal Cancer > Cardiotoxicity: consider switching to S-1

Cardiotoxicity: consider switching to S-1

Expert
Prof. Pia Österlund, Tampere University Hospital, Finland

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO 2020
A retrospective cohort study of patients presenting with cardiotoxicity after treatment with fluoropyrimidines suggests that switching to S-1 (i.e. a combination of tegafur, gimeracil, and oteracil, at a molar ratio of 1:0.4:1) is safe for these patients and supports treatment continuation [1].

Prof. Pia Österlund (Tampere University Hospital, Finland) presented a multicentre retrospective cohort study, including patients with solid tumours who experienced fluoropyrimidine-related cardiotoxicity and were re-challenged with a different fluoropyrimidine or S-1 and then assessed for cardiotoxicity.

Cardiotoxicity during capecitabine (n=124), continuous (n=13), or bolus 5-fluorouracil (n=4) was reported for 141 patients prior to switching to S-1 therapy. Cardiotoxicity was defined as chest pain including vasospasm without cardiac findings (55%), acute coronary syndrome or myocardial infarction (32%), atrial fibrillation (4%), heart failure/cardiomyopathy (4%), tachycardia/bradycardia (3%), and/or other (15%). Grade 3-4 cardiotoxicity occurred in 55%, appeared on cycle 1-2 in 89%, and at a median 4 days (range 0-466) from fluoropyrimidine initiation. Causality was judged to be related in 26%, probable in 60%, and possible in 14%. Action with fluoropyrimidine causing cardiotoxicity was permanent discontinuation in 91%. Treatment intent was curative in 70%. Cumulative incidence of recurrent cardiotoxicity with S-1 was 3.5% (95% CI 1.2-8.4%) and median time to recurrent cardiotoxicity was 11 days (range 6-195). Out of 141 participants, 4 had grade 1 and 1 had grade 2 recurrent cardiotoxicity. S-1 was discontinued in 1 patient.

In conclusion, fluoropyrimidine-related cardiotoxicity, when encountered, is often considered severe, occurs early, and leads to permanent fluoropyrimidine discontinuation. Switching to a S-1-based therapy appears safe.


    1. Österlund P, et al. ASCO Virtual Meeting, 29-31 May 2020, Poster 7037.




Posted on